Tachykinins and kinins in airway allergy

Bibliography

• OTSUKA M, YOSHIOKA K: Neurotransmitter functions of mammalian tachykinins. Physiological. Rev. (1993) 73:229–308.
   PubMed Web of Science ®Google Scholar
• DI MARIA GU, BELLOFIORE S, GEPPETTI P: Regulation of airway neurogenic inflammation by neutral endopep-tidase. Eur. Respir. J. (1998) 12:1454–1462.
   PubMed Web of Science ®Google Scholar
• NADEL JA: Neutral endopeptidase modulates neurogenic inflammation. Eur. Respir. J. (1991) 4:745–754.
   PubMed Web of Science ®Google Scholar
• DONALDSON LF, HASKELL CA, HANLEY MR: Functionalcharacterization by heterologous expression of a novel cloned tachykinin peptide receptor. Biochem. J. (1996) 320:1–5.
   PubMed Web of Science ®Google Scholar
• MAGGI CA, SCHWARTZ TW: The dual nature of thetachykinin NKi receptor. Trends Pharmacol. ScL (1997) 18:351–355.
   PubMed Web of Science ®Google Scholar
• REGOLI D, BOUDON A, FAUCHERE J-L: Receptors and antagonists for substance P and related peptides. Pharmacol. Rev. (1994) 46:551–599.
   PubMed Web of Science ®Google Scholar
• MARCEAU F, HESS JF, BACHAROV DR: The B1 receptors for kinins. Pharmacol. Rev. (1998) 50:357–386.
   PubMed Web of Science ®Google Scholar
• REGOLI D, BARABE' J: Pharmacology of bradykinin and related kinins. Pharmacol. Rev. (1980) 32:1–46.
   PubMed Web of Science ®Google Scholar
• STERANKA L, MANNING D, DEHAAS C et al.: Bradykinin as a pain mediator: receptors are localized to sensory neurons, and antagonists have analgesic actions. Proc. Natl. Acad. Sci. USA (1988) 85:3245–3249.
   PubMed Web of Science ®Google Scholar
• HOLZER P: Local effector functions of capsaicin-sensitive sensory nerves endings: involvement of tachykinins, calcitonin gene-related peptide and other neuropeptides. Neuroscience (1988) 24:739–768.
   PubMed Web of Science ®Google Scholar
• MAGGI C: The pharmacology of the efferent function of sensory nerves. J. Auton. Pharmacol. (1991) 11:173–208.
   PubMedGoogle Scholar
• GEPPETTI P: Sensory neuropeptide release by bradyki-nin: mechanisms and pathophysiological implica-tions. Regu. PepL (1993) 47:1–23.
   PubMed Web of Science ®Google Scholar
• FROSSARD N, RHODEN KJ, BARNES PJ: Influence of epithelium on guinea pig airway responses to tachyki-nins: role of endopeptidase and cyclooxygenase. J. Pharmacol. Exp. Ther. (1989) 248:292–298.
   PubMed Web of Science ®Google Scholar
• FIGINI M, EMANUELI C, BERTRAND C et al: Evidence that tachykinins relax the guinea-pig trachea via nitric oxide release and by stimulation of a septide-insensitive NKi receptor. Br. J. Pharmacol. (1996) 115:128–132.
   Google Scholar
• ADVENIER C, LAGENTE V, BOICHOT E: The role of tachykinin receptor antagonists in the prevention of bronchial hyperresponsiveness, airway inflammation and cough. Eur. Respir. J. (1997) 10:1892–1906.
   PubMed Web of Science ®Google Scholar
• ADVENIER C, NALINE E, TOTY L et al.: Effects on theisolated human bronchus of SR 48968, a potent and selective nonpeptide antagonist of the neurokinin A (NK2) receptors. Am. Rev. Respir. Dis. (1 99 2) 146:1177–1181.
   Google Scholar
• BERTRAND C, NADEL JA, GRAF PD et al: Capsaicinincreases airflow resistance in guinea pigs in vivo by activating both NK2 and NK1 tachykinin receptors. Am. Rev. Respir. Dis. (1993) 148:909–914.
   PubMed Web of Science ®Google Scholar
• NALINE E, MOLIMARD M, REGOLI D et al: Evidence forfunctional tachykinin NK1 receptors on human isolated small bronchi. Am. J. Physiol. (1996) 2 71:L763–767.
   Google Scholar
• PIEDIMONTE G, HOFFMAN JI, HUSSEINI WK et al: NK1receptors mediate neurogenic inflammatory increase in blood flow in rat airways. J. Appl. Physiol. (1993) 74:2462–2468.
   PubMed Web of Science ®Google Scholar
• BALUK P, BERTRAND C, GEPPETTI P et al.: NK1 receptorsmediate leukocyte adhesion in neurogenic inflamma-tion in the rat trachea. Am. J. Physiol. (1995) 268:L263–L269.
   PubMed Web of Science ®Google Scholar
• ROGERS DF, AURSUDKIJ B, BARNES PJ: Effects oftachykinins on mucus secretion in human bronchi in vitro. Eur. J. Pharmacol. (1989) 174:283–286.
   PubMed Web of Science ®Google Scholar
• GEPPETTI P, BERTRAND C, BACCI E et al.: Characteriza-tion of tachykinin receptors in the ferret trachea by peptide agonists and non-peptide antagonists. Am. J. Physiol. (1993) 265:L164–L169.
   PubMed Web of Science ®Google Scholar
• ICHINOSE M, BELVISI MG, BARNES PJ: Bradykinin-induced bronchoconstriction in guinea pig in vivo: role of neural mechanisms. J. Pharmacol Exp. Ther. (1990) 253:594–599.
   PubMed Web of Science ®Google Scholar
• BERTRAND C, GEPPETTI P, BAKER J et al.: Role ofpeptidases and NK1 receptors in vascular extravasa-tion induced by bradykinin in rat nasal mucosa. J. Appl. Physiol. (1993) 74:2456–2461.
   PubMed Web of Science ®Google Scholar
• YOSHIHARA S, GEPPETTI P, HARA M et al.: Coldair-induced bronchoconstriction is mediated by tachykinin and kinin release in guinea pigs. Eur. J. Pharmacol. (1996) 296:291–296.
   PubMed Web of Science ®Google Scholar
• YOSHIHARA S, CHAN B, YAMAWAKI I et al: Plasma extravasation in the rat trachea induced by cold air is mediated by tachykinin release from sensory nerves. Am. J. Respir. Grit. Care Med. (1995) 151:1011–1017.
   PubMed Web of Science ®Google Scholar
• RICCIARDOLO FLM, RADO W, FABBRI LM et al.: Broncho-constriction induced by citric acid inhalation in guinea pigs: role of tachykinins, kinins and nitric oxide. Am. J. Respir. Grit. Care Med. (1999) 159:557–562.
   PubMed Web of Science ®Google Scholar
• RICCIARDOLO FLM, NADEL JA, GRAF PD et al: Role ofkinins in anaphylactic-induced bronchoconstriction mediated by tachykinins in guinea-pigs. Br. J. Pharmacol. (1994) 113:508–512.
   PubMed Web of Science ®Google Scholar
• BERTRAND C, GEPPETTI P, BAKER J et al.: Role ofneurogenic inflammation in antigen-induced vascular extravasation in guinea pig trachea. J. Immunol. (1993) 150:1479–1485.
   PubMed Web of Science ®Google Scholar
• BERTRAND C, GEPPETTI P, GRAF PD et al. Involvement of neurogenic inflammation in antigen-induced bronchoconstriction in guinea pigs. Am. J. Physiol (1993) 265:L507–L511.
   PubMed Web of Science ®Google Scholar
• BERTRAND C, NADEL JA, YAMAWAKI I et al.: Role ofkinins in the vascular extravasation evoked by antigen and mediated by tachykinins in guinea pig trachea. J. Immunol. (1993) 151:4902–4907.
   PubMed Web of Science ®Google Scholar
• BERTRAND C, GEPPETTI P: Tachykinin and kinin receptor antagonists: therapeutic perspectives in allergic diease. Trends Pharmacol ScL (1996) 17:255–259.
   PubMed Web of Science ®Google Scholar
• ICHINOSE M, NAKAJIMA N, TAKAHASHI T et al.: Protec-tion against bradykinin-induced bronchoconstriction in asthmatic patients by neurokinin receptor antago-nist. Lancet (1992) 340:1248–1251.
   PubMed Web of Science ®Google Scholar
• SNIDER R, CONSTANTINE J, LOWE J et al: A potent nonpeptide antagonist of the substance P (NK1) receptor. Science (1991) 251:435–437.
   PubMed Web of Science ®Google Scholar
• SCHMIDT AW, MCLEAN S, HEYM J: The substance P receptor antagonist CP-96,345 interacts with Ca2+ channels [corrected and republished article originally printed in Eur J Pharmacol 1992]. Eur. J. Pharmacol (1992) 219:491–492.
   PubMedGoogle Scholar
• MCLEAN S, GANONG A, SEYMOUR PA et al: Pharma-cology of CP-99,994; a nonpeptide antagonist of the tachykinin neurokinin-1 receptor. J. Pharmacol. Exp. Ther. (1993) 267:472–479.
   PubMed Web of Science ®Google Scholar
• DELAY-GOYET P, LUNDBERG JM: Cigarette smoke-induced airway oedema is blocked by the NK1 antago-nist, CP-96,345. Eur. J. Pharmacol. (1991) 203:157–158.
   PubMed Web of Science ®Google Scholar
• GARRET C, CARRUETTE A, FARDIN V et al.: Pharma-cological properties of a potent and selective nonpep-tide substance P antagonist. Proc. Natl. Acad. Sci. USA (1991) 88:10208–10212.
   PubMed Web of Science ®Google Scholar
• EMONDS-ALT X, DOUTREMEPUICH JD, HEAULME Metal.: In vitro and in vivo biological activities of SR140333, a novel potent non-peptide tachykinin NK1 receptor antagonist. Eur. J. Pharmacol (1993) 250:403–413.
   Google Scholar
• EMONDS-ALT X, VILAIN P, GOULAOUIC P et al: A potent and selective non-peptide antagonist of the neurokinin A (NK2) receptor. Life Sci. (1992) 50:L101–106.
   Web of Science ®Google Scholar
• MAGGI CA, ASTOLFI M, GIULIANI S et al: MEN 10,627, a novel polycyclic peptide antagonist of tachykinin NK2 receptors. J. Pharmacol. Exp. Ther. (1994) 271:1489–1500.
   PubMed Web of Science ®Google Scholar
• MCELROY AB, CLEGG SP, DEAL MJ et al.: Highly potent and selective heptapeptide antagonists of the neurokinin NK-2 receptor. J. Med. Chem. (1992) 35:2582–2591.
   PubMed Web of Science ®Google Scholar
• CATALIOTO RM, CRISCUOLI M, CUCCHI P et al.: MEN11420 (Nepadutant), a novel glycosylated bicyclic peptide tachykinin NK2 receptor antagonist. Br. J. Pharmacol. (1998) 123:81–91.
   PubMed Web of Science ®Google Scholar
• DAOUI S, COGNON C, NALINE E et al.: Involvement oftachykinin NK3 receptors in citric acid-induced cough and bronchial responses in guinea pigs. Am. J. Respir. Grit. Care Med. (1998) 158:42–48.
   PubMed Web of Science ®Google Scholar
• GIARDINA GA, SARAU HM, FARINA C et al.: Discovery ofa novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 1. Identification of the 4- quinolinecarboxamide framework. J. Med. Chem. (1997) 40:1794–1807.
   Google Scholar
• MURAI M, MORIMOTO H, MAEDA Y et al.: Effects ofFK224, a novel compound NK1 and NK2 receptor antagonist, on airway constriction and airway edema induced by neurokinins and sensory nerve stimula-tion in guinea pigs. J. Pharmacol. Exp. Ther. (1992) 262:403–408.
   PubMed Web of Science ®Google Scholar
• KUDLACZ EM, KNIPPENBERG RW, LOGAN DE et al: The effect of MDL 105,212, a nonpeptide NK1/NK2 receptor antagonist in an allergic guinea pig model. J. Pharmacol. Exp. Ther. (1996) 279:732–739.
   PubMed Web of Science ®Google Scholar
• ROBINEAU P, LONCHAMPT M, KUCHARCZYK N et al.: In vitro and in vivo pharmacology of S 16474, a novel dual tachykinin NK1 and NK2 receptor antagonist. Eur. J. Pharmacol. (1995) 294:677–684.
   PubMed Web of Science ®Google Scholar
• HOCK F, WIRTH K, ALBUS U et al.: HOE 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br. J. Pharmacol (1991) 102:769–773.
   PubMed Web of Science ®Google Scholar
• FIGINI M, RICCIARDOLO FLM, JAVDAN P et al.: Evidence that epithelium-derived relaxing factor released by bradykinin in the guinea-pig trachea is nitric oxide. Am. J. Respir. Crit. Care Med. (1996) 153:918–923.
   PubMed Web of Science ®Google Scholar
• SAWUTZ DG, SALVINO JM, DOLLE RE et al: The nonpep-tide WIN 64338 is a bradykinin B2 receptor antagonist. Proc. Natl. Acad. Sci. USA (1994) 91:4693–4697.
   PubMed Web of Science ®Google Scholar
• ASANO M, INAMURA N, HATORI C et al: The identifica-tion of an orally active, nonpeptide bradykinin B2 receptor antagonist, FR173657. Br. J. Pharmacol. (1997) 120:617–624.
   PubMed Web of Science ®Google Scholar
• GRIESBACHER T, LEGAT FJ: Effects of FR173657, a non-peptide B2 antagonist, on kinin-induced hypotension, visceral and peripheral oedema formation and bronchoconstriction. Br. J. Pharmacol. (1997) 120:933–939.
   PubMed Web of Science ®Google Scholar
• MORI T, IMAMURA T: Inhibition of guinea pig skin allergic reactions by nonpeptide bradykinin B2 receptor antagonist FR173657. Int. Arch. Allergy Immunol. (1998) 116:278–283.
   PubMed Web of Science ®Google Scholar
• KOROGHI H, GRAF PD, SEKIZAWA K et al: Netral endopeptidase inhibitors potentiate substance P and capsaicin-induced cough in awake guinea-pigs. J. Clin. Invest. (1988) 82:2063–2068.
   PubMed Web of Science ®Google Scholar
• ARONOW WS: The ELITE Study. What are its implica-tions for the drug treatment of heart failure? Evalua-tion of Losartan in the Elderly Study. Drugs Aging (1998) 12:423–428.
   Google Scholar
• FEATHERSTONE RL, PARRY JE, EVANS DM et al.:Mechanism of irritant-induced cough: studies with a kinin antagonist and a kallikrein inhibitor. Lung (1996) 174:269–275.
   PubMed Web of Science ®Google Scholar
• FOX AJ, UMESH GL, BELVISI M eta].: Bradykinin-evokedsensitization of airways sensory nerves: a mechanism for ACE-inhibitor cough. Nature Med. (1996) 2:814–817.
   Google Scholar
• EMANUELI C, GRADY EF, MADEDDU P et al.: Acute ACEinhibition causes plasma extravasation in mice that is mediated by bradykinin and substance P. Hypertension (1998) 31:1299–1304.
   PubMed Web of Science ®Google Scholar
• GIRARD V, NALINE E, VILAIN P et al: Effect of the two tachykinin antagonists, SR 48968 and SR 140333, on cough induced by citric acid in the unanaesthetized guinea pig. Eur. Respir. J. (1995) 8:1110–1114.
   PubMed Web of Science ®Google Scholar
• UJIIE Y, SEKIZAWA K, AIKAWA T et al: Evidence for substance P as an endogenous substance causing cough in guinea pigs. Am. Rev. Respir. Dis. (1993) 148:1628–1632.
   PubMed Web of Science ®Google Scholar
• ADVENIER C, DAOUI S, CUT YY et al: Inhibition by thetachykinin NK3 receptor antagonist, SR 142801, of substance P-induced microvascular leakage hypersen-sitivity and airway hyperresponsiveness in guinea-pigs. Am. J. Respir. Crit. Care Med. (1996) 153:A163.
   PubMedGoogle Scholar
• BOLSER DC, DEGENNARO FC, O'REILLY S et al: Central antitussive activity of the NK1 and NK2 tachykinin receptor antagonists, CP-99,994 and SR 48968, in the guinea-pig and cat. Br. J. Pharmacol. (1997) 121:165–170.
   PubMed Web of Science ®Google Scholar
• JOOS G, SCOOR JV, KIPS JC et al: The effect of inhaled FK224, a tachykinin NK-1 and NK-2 receptor antago-nist, on neurokinin A-induced bronchoconstriction in asthmatics. Am. J. Respir. Crit. Care Med. (1996) 153:1781–1784.
   PubMed Web of Science ®Google Scholar
• LUNDE H, HEDNER J, SVEDMIR N: Lack of efficacy of 4weeks treatment with the neurokinin receptor antago-nist FK244 in mild to moderate asthma. Eur. Respir. J. (1994) 7\(Suppl. 18):248s.
   Google Scholar
• VAN SCHOOR J, JOOS GF, CHASSON B eta].: The effect ofSR 48968, a nonpeptide neurokinin-2 receptor antago-nist on neurokinin A-induced bronchocostriction in asthmatics. Eur. Respir. J. (1996) 9:289s.
   Google Scholar
• FAHY JV, WONG HH, GEPPETTI P et al.: Effect of an NK-1receptor antagonist (CP-99,994) on hypertonic saline-induced bronchoconstriction and cough in male asthmatic subjects. Am. J. Respir. Crit. Care Med. (1995) 152:879–884.
   PubMed Web of Science ®Google Scholar
• ICHINOSE M, MIURA M, YAMAUCHI H et al.: A neurokinin 1-receptor antagonist improves exercise-induced airway narrowing in asthmatic patients. Am. J. Respir. Crit. Care Med. (1996) 153:936–941.
   PubMed Web of Science ®Google Scholar
• AKBARY AM, WIRTH KJ, SCHOLKENS BA: Efficacy and tolerability of Icatibant (Hoe 140) in patients with moderately severe chronic bronchial asthma. Immunopharmacology (1996) 33:238–242.
   PubMed Web of Science ®Google Scholar
• KRAMER MS, CUTLER N, FEIGHNER J et al.: Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science (1998) 281:1640–1645.
   PubMed Web of Science ®Google Scholar
• FUJII T, MURAI M, MORIMOTO H eta].: Pharmacologicalprofile of a high affinity dipeptide NK1 receptor antagonist, FK888. Br. J. Pharmacol (1992) 107:785–789.
   Google Scholar
• ROBINEAU P, PETIT C, STACZEK J et al. NK1 and NK2 receptors involvement in capsaicin-induced cough in guinea-pigs. Am. J. Respir. Grit. Care Med. (1994) 149:A186.
   Google Scholar
• WALPOLE CS, BROWN MC, JAMES IF et al.: Comparative,general pharmacology of SDZ NKT 343, a novel, selective NK1 receptor antagonist. Br. J. Pharmacol. (1998) 124:83–92.
   PubMed Web of Science ®Google Scholar
• GITTER BD, BRUNS RF, HOWBERT JJ et al.: Pharma-cological characterization of LY303870: a novel, potent and selective nonpeptide substance P (neurokinin-1) receptor antagonist. J. Pharmacol. Exp. Ther. (1995) 275:737–744.
   PubMed Web of Science ®Google Scholar
• BALUK P, BERTRAND C, GEPPETTI P et al.: NK1 receptorantagonist CP-99,994 inhibits cigarette smoke-induced neutrophil and eosinophil adhesion in rat tracheal venules. Exp. Lung Res. (1996) 22:409–418.
   PubMed Web of Science ®Google Scholar
• TURNER CR, ANDRESEN CJ, PATTERSON DK: Dual antagonism of NK1 and NK2 receptors by CP 99,994 and SR 48968 prevents airway hyperresponsiveness in primates. Am. J. Respir. Grit. Care Med. (1996) 153:A160.
   Google Scholar
• BOICHOT E, GERMAIN N, LAGENTE V et al.: The tachyki-nin NK2 receptor antagonist, SR 48968, prevents substance P-induced hyperresponsiveness in guinea-pigs. Br. J. Pharmacol. (1995) 114:259–261.
   PubMed Web of Science ®Google Scholar
• MIZUGUCHI M, FUJIMURA M, AMEMIYA T et al: Involve-ment of NK2 receptors rather than NK1 receptors in bronchial hyperresponsiveness induced by allergic reaction in guinea-pigs. Br. J. Pharmacol. (1996) 117:443–448.
   PubMed Web of Science ®Google Scholar
• SCHEERENS H, BUCKLEY TL, MUIS T et al.: The involve-ment of sensory neuropeptides in toluene diisocyanate-induced tracheal hypereactivity in the mouse airways. Br. J. Pharmacol (1996) 119:1665–1671.
   PubMed Web of Science ®Google Scholar
• EVANGELISTA S, BALLATI J, PERRETTI F: MEN 10,627 a new selective antagonist NK2 receptor antagonist inhibits antigen induced bronchoconstriction in sensitized guinea-pigs. Neuropeptides (1994) 26:39–40.
   PubMedGoogle Scholar
• SCHMIDT D, JORRES RA, RABE KF et al.: Reproducibility of airway response to inhaled bradykinin and effect of the neurokinin receptor antagonist FK-224 in asthmatic subjects. Eur. J. Clin. Pharmacol. (1996) 50:269–273.
   PubMed Web of Science ®Google Scholar
• HONDA I, KOHROGI H, YAMAGUCHI T et al.: Tachykinin antagonist FK224 inhibits neurokinin A-, substance P-and capsaicin-induced human bronchial contraction. Fundam. Gun. Pharmacol. (1997) 11:260–266.
   PubMed Web of Science ®Google Scholar
• CORBOZ MR, RIVELLI MA, RAMOS SI et al.: Tachykinin NK1 receptor-mediated vasorelaxation in human pulmonary arteries. Eur. J. Pharmacol. (1998) 350:R1–3.
   PubMed Web of Science ®Google Scholar